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New sequencing technologies allow genomic variation to be surveyed in much greater detail than previously possible.
While detailed analysis of a single individual typically requires deep sequencing, when many individuals are sequenced it is
possible to combine shallow sequence data across individuals to generate accurate calls in shared stretches of chromosome.
Here, we show that, as progressively larger numbers of individuals are sequenced, increasingly accurate genotype calls can
be generated for a given sequence depth. We evaluate the implications of low-coverage sequencing for complex trait
association studies. We systematically compare study designs based on genotyping of tagSNPs, sequencing of many
individuals at depths ranging between 23 and 303, and imputation of variants discovered by sequencing a subset of
individuals into the remainder of the sample. We show that sequencing many individuals at low depth is an attractive
strategy for studies of complex trait genetics. For example, for disease-associated variants with frequency >0.2%, se-
quencing 3000 individuals at 43 depth provides similar power to deep sequencing of >2000 individuals at 303 depth
but requires only ~20% of the sequencing effort. We also show low-coverage sequencing can be used to build a reference
panel that can drive imputation into additional samples to increase power further. We provide guidance for investigators
wishing to combine results from sequenced, genotyped, and imputed samples.
[Supplemental material is available for this article. Software implementing the methods is available at http://genome.
sph.umich.edu/wiki/Thunder.]
Genomewide association studies (GWAS), which examine hundreds
of thousands of common genetic variants in thousands of in-
dividuals, have resulted in the association of >1000 genetic loci
with specific traits and diseases (Hindorff et al. 2009; www.genome
.gov/gwastudies/). In the next few years, improved genotyping chip
designs and next generation sequencing technologies will allow
these studies to extend beyond common variants and systematically
evaluate rarer variants, insertion deletion polymorphisms, and larger
copy number variants—potentially expanding our understanding
of complex trait architecture (Maher 2008; Manolio et al. 2009).
Emerging sequencing technologies (Margulies et al. 2005;
Bentley 2006; Mardis 2008; Shendure and Ji 2008) can now generate
millions of short reads (typically 30–200 bp in length) inexpensively
but with relatively high error rates (0.5%–1.0% error per raw base
is typical). Standard genotype-calling algorithms rely on redundant
sequencing of each base to distinguish sequencing errors from true
polymorphisms (Ley et al. 2008; Li et al. 2008; Li et al. 2009b; Bansal
et al. 2010). For example, 303 read depth (where each position is
covered by an average of 30 reads) typically results in >99% geno-
typing accuracy (Bentley et al. 2008). While deep sequencing ap-
proaches have proven successful in the study of Mendelian disor-
ders (Ng et al. 2009; Lupski et al. 2010; Ng et al. 2010; Nikopoulos
et al. 2010; Roach et al. 2010), their application to complex trait
studies—which may require sequencing hundreds or thousands of
individuals—remains challenging due to high sequencing costs and
limits of existing sequencing capacity.
We have previously outlined a Hidden Markov Model (HMM)-
based approach for the analysis of shotgun sequence data across
many individuals (Li et al. 2010b). The approach identifies stretches
of chromosome shared among individuals and uses the information
to call genotypes from low-coverage sequence data more effectively.
The underlying principle is that pairs of chromosomes which share
a series of alleles flanking a site of interest are likely to also exhibit
identical alleles at that site. In this paper, we evaluate the impact
of the model on genotype calling, using both real (The 1000 Ge-
nomes Project Consortium 2010) and simulated data, and consider
its implications for the design of complex trait association studies.
We show that the proposed model for combining information
across individuals is highly effective. Even with 23–43 sequencing,
common and low frequency SNPs [minor allele frequency (MAF) >
0.5%] can be discovered and genotyped with high confidence.
Using simulations, we evaluate the trade-offs involved in deep se-
quencing of a few individuals and shallower sequencing of larger
numbers of individuals. We also discuss several other existing
methods that can perform genotype calling from low-coverage se-
quence data (Browning and Yu 2009; Le and Durbin 2010; McKenna
et al. 2010). More importantly, we systematically compare study
designs based on genotyping of tagSNPs, sequencing of many in-
dividuals at depths ranging between 23 and 303 and imputation
of variants discovered by sequencing in a subset of individuals into
the remainder of the sample. Our results show that low-coverage
sequencing provides a powerful and cost-effective alternative to se-
quencing smaller numbers of individuals at high depth. In addition,
5Corresponding author.
E-mail goncalo@umich.edu; fax (734) 615 8322.
Article published online before print. Article, supplemental material, and pub-
lication date are at http://www.genome.org/cgi/doi/10.1101/gr.117259.110.
940 Genome Research
www.genome.org
21:940–951  2011 by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/11; www.genome.org
we show that imputation into additional samples can increase
power further.
Results
To evaluate the performance of low-coverage sequencing with re-
spect to SNP discovery, genotype calling accuracy, and power for
genetic association studies, we carried out a series of simulations
and analyses of real data sets. Here, we first describe results ob-
tained using simulated data (with respect to power for SNP dis-
covery and accuracy of the genotypes assigned to each individual)
and then report results of similar analysis on pilot data generated
by the 1000 Genomes Project (The 1000 Genomes Project Con-
sortium 2010). Next, we consider the impact of these methods on
genetic association studies in two ways: (1) by estimating r2, the
squared correlation between genotypes estimated using various
low-pass sequencing designs and true simulated genotypes, a
quantity which varies between 0 and 1 and which can be used to
calculate n 3 r2, the effective sample size attainable by low-pass
sequencing of n individuals, such that deep sequencing of n 3 r2
individuals would provide approximately equivalent power; r2
depends on the number of individuals sequenced (more is better),
the depth of sequencing for each individual (higher is better), the
allele frequency of interest (higher is better), and population his-
tory; and (2) by directly simulating various case-control samples
and using these to evaluate the power of different study designs.
Finally, since genotype imputation is now widely used in the
analysis of genetic association studies, we evaluate the utility of
genotype imputation using reference panels constructed using
low-pass sequencing data.
SNP discovery: Simulations
We first used simulation studies to assess the performance of low-
pass sequencing in SNP discovery, with a focus on less common
variants (MAF < 5%). We first simulated 45,000 chromosomes for
a series of ten 100-kb regions, using a coalescent model that mimics
HapMap LD patterns, accounts for variation in local recombination
rates, and models population demography realistically (Schaffner
et al. 2005). We simulated reads that were 32-bp-long, with a per bp
error rate of 0.5%. Very roughly, these correspond to the perfor-
mance of early versions of the sequencing-by-synthesis Illumina
Genome Analyzer technology (Bentley et al. 2008). We then simu-
lated short read data for between 30 and 2000 individuals, each
sequenced at between 23 and 63 depth. Read start positions were
sampled randomly such that each base had an equal probability of
being selected as the starting point for a read, and the resulting
depth per locus per individual follows a Poisson distribution. Our
simulation did not incorporate sampling biases in read start posi-
tions (e.g., due to GC content) or preference for particular alleles and
thus corresponds to an idealized case. After simulation, we applied
the proposed LD-based method to identify polymorphic sites and
assign individual genotypes. Due to the large number of bases ex-
amined and the sequencing error rate, the raw read data suggested
a large number of false polymorphic sites (false positives). True
polymorphic sites typically appeared in multiple reads derived from
the same individual or in reads from different individuals who share
a haplotype flanking the potential polymorphism. This first set of
simulations thus evaluates the ability of the proposed model to
distinguish true polymorphisms from sequencing errors.
Figure 1 shows how the number of detected SNPs changes as
a function of sequencing depth and the number of individuals
sequenced by population MAF (i.e., MAF calculated using all
45,000 chromosomes). Rarer variants are more difficult to detect
because it is challenging to distinguish genuine rare alleles from
sequencing errors, particularly when individuals are sequenced at
low depth. For example, suppose 100 individuals are sequenced,
and two reads are obtained for every individual overlapping
a particular locus. Further, suppose that two copies of the reference
allele are observed in 99 of the sequenced individuals and that one
copy of the reference allele and one copy of an alternative allele
are observed in the 100th individual. With a sequencing error of
;0.5% and no additional information, it would be impossible
to tell if the alternative allele reflects a true heterozygote or a se-
quencing error. We see from Figure 1 that, whereas 100% of com-
mon variants with MAF > 5% can be detected when just 100 in-
dividuals are sequenced at depth 23, only ;3.8% of variants with
MAF < 0.1% (<45 copies of the minor allele among the 45,000
chromosomes) can be detected even when 500 individuals are se-
quenced at depth 63. The proportion of variants identified is
bounded upwards by the proportion of polymorphisms in the
population that segregate among sequenced individuals, which
varies with MAF. For example, the chance that a MAF = 5% SNP is
polymorphic among 60 individuals is ;99.8%, while for a MAF =
0.1% SNP, it is only 11.3%. Dotted lines in Figure 1 show this
theoretical upper bound. For comparison, we also present the de-
tection power at depth 303 (bottom right panel), which largely
overlaps with the theoretical upper bound as expected. Effectively,
as more individuals are sequenced, a larger fraction of the variants
actually present in the sample can be identified. This is because
SNP discovery is dominated by two factors: the number of times
the alternate allele is present among sequenced individuals, and
the number of individuals where multiple reads support the al-
ternate allele. Lastly, for low-frequency SNPs, the power of variant
detection is also heavily influenced by the number of false posi-
tives allowed, which are tabulated in Supplemental Table 1. In
general, we allowed more false positives when fewer individuals
were sequenced.
Genotyping accuracy: Simulations
The proposed method estimates individual genotypes for detected
variants. Figure 2 presents the genotypic concordance and r2 by
minor allele frequency, with the former being the percentage of
genotypes inferred correctly when genotypes assigned by the
proposed model are compared with the true simulated genotypes,
and the latter being the squared correlation between the inferred
allele dosages (estimated fractional counts of an arbitrary allele for
each SNP, ranging from 0.0 to 2.0) and the true allele counts (an
integer quantity taking values 0, 1, or 2). While the first measure is
a natural summary of genotyping accuracy, the latter measure is
more directly related to power and sample size requirements for
association mapping (Pritchard and Przeworski 2001).
Figure 2 shows that highly accurate genotype inference can be
made using lower depth sequencing. At depth 43, >98% genotypic
concordance is achieved across the examined MAF spectrum with
as few as 60 sequenced individuals. For sites with low MAF, the
overall genotypic concordance measure can be misleading because
a rate of (1MAF)2 3 100% can be achieved by simply assigning all
individuals to be homozygous for the reference allele. (Such a
strategy, while ‘‘accurate’’, would not be helpful for genetic asso-
ciation studies. Comparisons with such a ‘‘straw-man’’ approach
are presented in Supplemental Figure 1.) In general, rarer genotypes
are more difficult to call, and this is reflected in lower concordance
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rates for heterozygotes and minor allele homozygotes (Fig. 3; Sup-
plemental Figs. 2 and 3) as well as in lower values of the r2 statistic
for markers with low MAF (Fig. 2, right panel). To improve accuracy
for sites with a low minor allele frequency, it is necessary to increase
sample size (see Supplemental Figs. 2 and 3). Note also that as
sample size increases, the fraction of genotypes falling into the most
difficult to call configurations (i.e., where the true genotypes are
non-reference homozygotes at a low frequency variant site) de-
creases. For example, while ;2% of genotypes are non-reference
homozygotes for alleles with count <10 when 30 individuals are
sequenced at 23 (Supplemental Fig. 2), <0.2% genotypes fall under
that category when 500 individuals are sequenced at 63 (Supple-
mental Fig. 3).
Counter intuitively, dosage r2 for sites with low MAF can de-
crease with increasing sample size, for example, for SNPs with MAF
0.1%–0.2%, r2 is 64% when 30 individuals are sequenced at 23 but
53% when 500 individuals are sequenced at the same depth. We
anticipated that the LD-based HMM, by borrowing information
across individuals, would generate haplotypes that are progres-
sively more accurate as additional individuals are sequenced.
This is counterbalanced by a ‘‘winner’s curse’’ phenomenon: Call-
ing accuracy (measured by genotypic concordance or per-marker
information content, n 3 r2) can only be evaluated at detected
polymorphic sites, and larger samples, which allow detection of
many more polymorphic sites, also include many configurations
that are harder to call. When we repeated our evaluation but fo-
cused only on sites that were detected at all sequencing depths
(which we call ‘‘easy-to-detect’’ sites), we found that dosage r2 in-
creased with sample size as expected. For example, for a fixed set
of detected SNPs with MAF < 0.5% and average sequencing depth
of 23, average r2 increased from 66% to 80% to 94% as sample size
increased from 30 to 100 to 500 (Supplemental Fig. 4). As expected,
the improved performance in larger samples is partly explained by
the increasingly long stretches of chromosome shared among se-
quenced individuals, which become progressively easier for the
LD-aware model to identify. These longer stretches likely originate
in a more recent common ancestor and are also less likely to be
disturbed by mutation or gene conversion events.
SNP discovery and genotype accuracy: Empirical evaluation
While analyses of simulated data can highlight important features
of the proposed LD-aware method, they don’t take into account many
of the practical challenges of deploying low-coverage sequencing in
Figure 1. SNP discovery (%) by MAF, sequencing depth, and sequencing sample size. We simulated 30–2000 individuals sequenced at depths
23, 43, 63, and 303. We plotted the % of SNPs discovered by population MAF category (<0.1% to >5%), where population MAF is for the 45,000





real life settings. For example, in real data sets, many short reads
might be mismapped, creating false evidence for polymorphisms.
In addition, incorrect alignment of sequences near short in-
sertion deletion polymorphisms might generate false evidence
for SNPs and further disrupt calling. To evaluate the real life
performance of the proposed methods, we used data gener-
ated by the 1000 Genomes Project (The 1000 Genomes Project
Consortium 2010). The 1000 Genomes Project aims to detect all
variants with frequency >1% in several continental regions by se-
quencing ;2500 unrelated individuals at ;43depth. In its pilot
phase, the project sequenced 179 unrelated individuals from the
CEU, CHB+JPT, and YRI populations at an average depth of 2–43.
We used the proposed HMM model to analyze the data (using
the steps summarized in Fig. 4). Since individuals sequenced in this
low-coverage pilot were also genotyped at ;1.4 million SNPs in
Phase III of the International HapMap Project (The International
HapMap Consortium 2007) using the Illumina 1M and the Affy-
metrix 6.0 SNP arrays, and we expected that a scaffold of high
quality genotypes might aid the model’s ability to identify shared
haplotypes, we integrated these HapMap 3 genotypes into our
analysis of the sequence data. Here, we also repeated our analysis
removing HapMap genotype information so that results can be
fairly compared with those from simulations. Since the number
of individuals with genotypes at HapMap 2 specific sites varies
among CEU, CHB+JPT, and YRI, our comparisons all use a random
subset of 43 individuals for each panel (43 CEU, 43 CHB+JPT, and
the 43 YRI) and for our simulated data.
Figure 5 illustrates detection power by plotting the percentage
of HapMap sites detected by minor allele count (out of 43). As ex-
pected, less common SNPs are harder to detect: Only 21%–44% of
singleton SNPs and 54%–76% of doubleton SNPs can be detected,
but 96%–100% of SNPs with a minor allele appearing 6–10 times
were detected. We note that, by examining sequence data for 60
individuals but array genotypes for only 43 individuals, our results
may overestimate detection power for a given minor allele count
(particularly for singletons and doubletons) but underestimate
detection power for a given minor allele frequency. For example,
when 60 CEU samples are sequenced, nominal power to detect
singletons is estimated to be 35.6%, 45.1%, and 65.3%, if the eval-
uation uses 60, 40, or 20 individuals, respectively (Supplemental
Figure 2. Genotype calling quality by MAF, sequencing depth, and sequencing sample size. We simulated 30–2000 individuals sequenced at depths
23, 43, and 63. We compared genotype calls at detected SNPs with the simulated truth to obtain two measures of genotype calling quality, genotypic
concordance and dosage r2, for each called SNP. We plot these two measures (left panel: genotypic concordance; right panel: dosage r2) by population
MAF category (<0.1% to >5%), where population MAF is for the 45,000 simulated chromosomes.
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Table 2). This finding can be easily explained: When assessing
detection rate by minor allele count (MAC), some singleton SNPs
(MAC = 1) among 20 or 40 individuals might correspond to alleles
seen multiple times among the 60 sequenced individuals. For
MAF = 2.5%, the detection rates are 65.3%, 81.7%, and 87.7%,
respectively, when evaluation focuses on SNPs discovered among
20 individuals (MAC = 1), 40 individuals (MAC = 2), and among 60
individuals (MAC = 3). In this latter case, note that several of the
SNPs seen once among 20 individuals may actually have frequency
<2.5% in the larger set of 60 sequenced individuals.
For each called SNP, the model estimates r2 between called
genotypes and (unobserved) true genotypes as a measure of ge-
notype call accuracy. As expected, we have found that excluding
sites with low estimated r2 results in higher quality sets of SNP calls
(Browning and Yu 2009; Li et al. 2010b). For example, in the
original calls for the 1000 Genomes CEU sample, focusing on sites
with r2 greater than 0.0, 0.3, and 0.5 increases the ratio of transi-
tion to transversion SNPs from 1.86 to 1.88 and then to 1.97, ex-
cluding 0%, 5%, and 17% of the initial set of SNPs. For known sites,
this ratio slightly exceeds 2.0 across the genome and is often used
to evaluate overall SNP call set quality (Zhao and Boerwinkle 2002;
Zhang and Gerstein 2003).
Genotype calling accuracy in the 1000 Genomes Project Pilot
samples (CEU, CHB+JPT, and YRI), measured by overall genotypic
concordance and dosage r2, is presented in Figure 6, together with
a summary of performance in our previously described simula-
tions. Reassuringly, analysis of simulated and real data led to
similar SNP discovery rates and genotype accuracies (measured
either as the fraction of concordant genotypes or using the dosage
r2 measure). For example, empirical genotypic concordance among
the CEU samples is >98%, very close to expectations from simu-
lations. While genotypic concordance varies little with MAF, in the
range examined the more informative r2 measure increases with
MAF, from ;85% for SNPs with MAF 1%–2%, to 88% for MAF
2%–5%, and to ;95% for MAF > 5%. Performance among the
CHB+JPT and YRI samples was slightly worse, particularly for rarer
SNPs, likely due to somewhat lower depth of coverage in these
two sample sets (The 1000 Genomes Project Consortium 2010)
and to the lower level of LD in YRI. In addition, we present in
Supplemental Figure 5 results when phase 3 HapMap genotypes
were integrated into analysis. As expected, calling accuracy im-
proved with the additional genotype data but not substantially.
For example, r2 increased from 84.86%, 75.28%, and 74.61% to
85.78%, 76.77%, and 76.18%, respectively, for CEU, CHB+JPT, and
YRI for SNPs with MAF 1%–2%.
Low-coverage versus high-coverage sequencing designs
We have so far shown that low-coverage sequencing of many in-
dividuals can be used to detect polymorphic sites and infer geno-
types when many individuals are sequenced, each at 23–63
depth. This capability has important implications for the design of
complex disease association studies, which require large sample
sizes to detect genetic variants of modest effect. The typical GWAS
examines several thousand individuals (McCarthy et al. 2008), and,
for a number of diseases/traits, meta-analyses involving >100,000
individuals have been carried out (Lindgren et al. 2009; Newton-
Cheh et al. 2009; Dupuis et al. 2010; Teslovich et al. 2010). We
expect that affordable designs for sequencing large numbers of
samples will be critically important for the successful transition
from GWAS to sequencing-based association studies. Given that
total sequencing capacity is limited, low-coverage sequencing al-
lows much larger numbers of individuals to be studied.
We first simulated two extreme alternatives using the same
procedure described earlier. The first included sequence data for
400 individuals, each covered at 303 average read depth. The
second included sequence data for 3000 individuals, each covered
at 43 average read depth. Both designs result in the same total
investment of sequencing capacity. Table 1 summarizes five sta-
tistics for the two designs: (1) the percentage of detected sites, (2)
the overall genotype concordance, (3) heterozygote concordance
(which is a more challenging benchmark of genotyping accuracy),
(4) dosage r2, and (5) total information content as measured by nr2,
where n is the number of individuals sequenced. Both designs had
nearly 100% power to detect variants with MAF > 0.5%, while the
low-coverage design provided greater power to detect less common
variants with MAF 0.2%–0.5%. Neither design had much power for
the rarest SNPs (MAF < 0.1%). For high-coverage designs, the minor
allele for rare SNPs was often absent from the sequenced sample;
Figure 4. Genotype calling pipeline for the 1000 Genomes Pilot 1
Project. The pipeline we have developed to call genotypes for individuals
sequenced at an average depth of ;4–53 by the 1000 Genomes Pilot 1
Project.
Figure 3. Genotype concordance and fraction of genotypes by non-
ancestral allele counts (60 individuals sequenced at 43). Genotype con-
cordance (y-axis on left, dots) and fraction of genotypes (y-axis on right,
bars) for simulated data, broken down by genotype category (homozy-
gotes for the ancestral allele [HomRef], heterozygotes [Het], and homo-
zygotes for the non-ancestral allele [HomAlt]) are plotted as a function of




for low-coverage designs, it was not possible to distinguish true
variants from sequencing errors confidently with a small number
of non-reference reads.
For detected variants, genotype accuracy was reduced for low-
coverage designs compared to high-coverage designs but was still
impressive. For example, for variants with MAF > 1%, the geno-
typic concordance was always >99.67%, and concordance at het-
erozygous sites was >97%. As noted previously, high rates of poly-
morphism discovery and reasonably accurate genotype inference
are possible because the model effectively combines information
across individuals with similar haplotypes, so that the coverage of
each haplotype is, effectively, quite deep. Thus, low-coverage de-
signs substantially increase the overall information content (even
when genotypes are individually not as good, in aggregate, they
contain more information), holding the
overall sequencing investment constant.
For example, for variants with MAF 0.1%–
0.2%, 0.2%–0.5%, 0.5%–1.0%, 1.0%–2.0%,
or 2.0%–5.0%, 43 sequencing of 3000 in-
dividuals provided effective sample sizes
measured by nr2 of 1917, 2069, 2406, 2758,
and 2873, corresponding to an effective
sample size 4.83, 5.23, 6.03, 6.93, and
7.23 greater than if 303 sequencing of
400 individuals were carried out. Note that
the boost in effective sample size holds for
any disease allele effect size.
Power of several design options
for sequencing-based genetic
association studies
To quantify further the benefits of low-
coverage designs for association mapping,
we carried out simulation studies directly
assessing statistical power to detect disease-
SNP association. For each of the ten re-
gions, we simulated 50 replicates of 1500
cases and 1500 controls, assuming one
causal SNP per simulated replicate per re-
gion. We focused on scenarios where the
causal variant is a low-frequency SNP with MAF ;0.1%, ;0.5%,
;1%, or ;3%. For each disease MAF, the effect size [as measured by
genetic relative risk (GRR)] was selected using CaTS (Skol et al.
2006) to achieve ;60% power when the causal SNP was genotyped
in 1000 cases and 1000 controls and tested for association at a
significance threshold of 0.05/200 = 0.00025 (200 is the approxi-
mate number of independent tests in each sequenced region). This
resulted in a GRR of 8.27, 3.25, 2.45, and 1.77 respectively, for
0.1%, 0.5%, 1%, and 3% disease MAF, respectively. In parallel, we
simulated 50 null sets by randomly sampling 6000 chromosomes
from the pool of 45,000 chromosomes and assigning these to the
1500 cases and 1500 controls at random.
We compared the following designs: tagSNP genotyping of
all 3000 samples, sequencing all 3000 individuals at depth 43,
sequencing progressively smaller numbers of individuals (2000,
1000, and 400) at progressively higher depths (63, 123, 303), and
a final set of designs that augment available sequence data through
imputation of discovered alleles into the remaining individuals,
using the tagSNP genotypes as a scaffold. TagSNPs were picked
to mimic Illumina HumanHap650K with an average coverage of
88% of the common (MAF > 5%) SNPs (see Li et al. 2010b for de-
tails). We used our packages MaCH and Thunder to generate ge-
notype calls, estimate allele dosages for sequenced individuals, and
impute genotypes from sequenced individuals into the remaining
individuals. Association analysis was performed using logistic re-
gression with allele dosages as the explanatory variable. Signifi-
cance thresholds were calibrated using the 500 null replicates and
selected to achieve a family-wise error rate of 5%.
Power is summarized in Table 2. First, consistent with the
substantial increase in information content shown in Table 1,
power increases substantially when sample size increases from 400
to 3000: from 4.0% to 61.6%, 6.4% to 75.6%, 7.4% to 82.8%, and
11.6% to 90.4% when disease MAF is 0.1%, 0.5%, 1%, or 3%, re-
spectively. In general, with fixed sequencing effort (total 12,0003
for the four different sequencing designs evaluated), low-coverage
Figure 6. Genotype calling quality: Simulated versus the 1000 Genomes Pilot 1. Genotype calling
quality is gauged by two measures—genotypic concordance and dosage r2—by comparing with true
genotypes in simulated data and with experimental genotypes in real data from the 1000 Genomes
Low-coverage Pilot Project. For both the real and simulated data, 60 individuals were sequenced at an
average depth of 43. For the 1000 Genomes Pilot 1 data, genotype calling was performed using se-
quencing data alone without HapMap 3 genotypes.
Figure 5. SNP detection power by minor allele count. For both simu-
lated CEU and real data sets from the 1000 Genomes Project, SNPs were
detected through a joint analysis of 59 or 60 individuals. Power of SNP
detection was evaluated using a subset of 43 individuals.
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sequencing of more individuals increases power compared to high-
coverage sequencing of fewer individuals.
Second, when a relatively small number of individuals are
sequenced, power can actually be lower than for designs that use
tagSNPs alone but examine larger numbers of individuals. For ex-
ample, in our simulation, tagSNP genotyping of 3000 individuals
had 30.8% power to detect disease-associated loci with MAF of
;3%, but sequencing of 400 individuals at 303 depth had only
11.6% power for the same MAF. This observation implies that deep
sequencing of modest numbers of individuals, although it allows
direct examination of much larger numbers of variants, may not
necessarily lead to new disease susceptibility loci that were missed
in GWAS.
Third, imputation from sequenced individuals into addi-
tional genotyped individuals can be extremely efficient. For ex-
ample, power increases from 17.8% to 41.8% for a 3% disease MAF
when variants detected in 1000 individuals sequenced at 123 are
imputed into the remaining 2000 individuals.
Fourth, we evaluated 20 combinations of sample size and
sequencing depth (sample size taking values 400, 1000, 2000, and
3000 and sequencing depth taking values 2, 4, 6, 12, and 30, in-
cluding the two designs assessed in Table 1) and directly assessed
power to detect disease SNPs with MAF 0.5%, 1%, or 3% (Fig. 7). As
expected, for the same number of individuals sequenced, power
increases with sequencing depth. For example, power increases by
an average of 8% when depth increases from 43 to 123 (i.e., tri-
pling sequencing effort). However, power typically increases even
more when total sequencing effort is increased by increasing the
number of sequenced individuals. For example, power is 7% for
disease MAF 0.5% when sequencing 1000 individuals at 43. If we
increase total sequencing effort to 12,0003, we can (1) sequence
the same 1000 individuals, increasing coverage to 123, or (2) se-
quence a total of 3000 individuals at 43. Option 1 results in 13.4%
power (6.4% power gain), while Option 2 results in 75.6% power
(68.6% power gain).
Reference panels based on low-coverage sequencing
Eventually, we expect that low-coverage sequencing will be
deployed in the context of many genetic association studies. In the
interim, many investigators will consider using the haplotypes
derived by low coverage sequencing of the 1000 Genomes Project
samples (or other samples) to impute missing genotypes in their
own samples. Thus, we set out to evaluate whether haplotypes
estimated using low-pass sequencing could provide a good refer-
ence for imputation of cataloged variants into existing GWAS data.
Table 1. Comparison of high-coverage (400 @ 303) and low-coverage (3000 @ 43) sequencing design given the same total
sequencing effort
Population MAF
Statistic Design 0.1%–0.2% 0.2%–0.5% 0.5%–1% 1%–2% 2%–5% >5%
% Discovery 400@303 65.41% 87.14% 100.00% 100.00% 100.00% 100.00%
3000@43 58.15% 94.39% 100.00% 100.00% 100.00% 100.00%
Overall genotypic concordance 400@303 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
3000@43 99.87% 99.75% 99.69% 99.75% 99.67% 99.81%
Heterozygote concordance 400@303 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
3000@43 82.48% 81.93% 90.39% 97.26% 98.84% 99.85%
Dosage r2 400@303 99.49% 99.61% 99.74% 99.81% 99.88% 99.98%
3000@43 63.90% 68.97% 80.21% 91.92% 95.77% 99.27%
Information content (nr2) 400@303 398 398 399 399 400 400
3000@43 1917 2069 2406 2758 2873 2978
% Discovery is the percentage of SNPs detected according to population MAF (MAF defined among 45,000 sequenced chromosomes). Overall genotypic
concordance is the percentage agreement between the inferred and simulated (i.e., true) genotypes. Heterozygote concordance is the percentage
agreement between the simulated (i.e., true) heterozygous genotypes and their inferred counterparts. Dosage r2 is the squared correlation between the
inferred allele dosages (ranging from 0 to 2) and true dosages. Information content, defined as n 3 r2, measures the overall information content across all
n sequenced individuals.
Table 2. Comparison of power to detect disease-SNP association: tagSNPs only; different sequencing designs with fixed sequencing cost;
and different sequencing designs with fixed sequencing cost plus imputation in additional individuals not sequenced
Disease SNP
Design MAF = 0.1% MAF = 0.5% MAF = 1% MAF = 3%
TagSNPs only, in 3000 individuals 5.0% 7.4% 12.0% 30.8%
400@303 4.0% 6.4% 7.4% 11.6%
400@303 + imputation into remaining 2600 10.4% 14.2% 15.0% 34.6%
1000@123 12.2% 13.4% 14.6% 17.8%
1000@123 + imputation into remaining 2000 15.6% 20.8% 25.6% 41.8%
2000@63 54.4% 57.8% 61.6% 82.2%
2000@63 + imputation into remaining 1000 56.2% 59.4% 61.8% 83.6%
3000 at 43 61.6% 75.6% 82.8% 90.4%
For sequencing and imputation into remaining samples, we removed SNPs with estimated r2 < 0.3. Association analysis was performed using logistic





Table 3 compares the utility of two alternative extreme designs for
building such a reference. In one design, 60 individuals are se-
quenced deeply at 163. In the alternative design, 400 individuals
are sequenced at 23. Roughly, these correspond to two hypo-
thetical designs considered at the outset of the 1000 Genomes
Project (The 1000 Genomes Project Consortium 2010). In each
case, we evaluate the utility of the resulting panel for imputation
into additional samples typed only for GWAS tagSNPs. For SNPs
with MAF > 0.5%, the low-coverage design clearly manifests its
advantages in terms of both variant discovery power and in-
formation content after imputation. For example, 14% more SNPs
with MAF 1%–2% can be imputed (with r2 > 0.3) using the hap-
lotypes derived from low-coverage sequencing of 400 individuals
than using haplotypes derived from deeper sequencing of 60 in-
dividuals. For SNPs that can be imputed, there is a ;7% increase
in r2 (from 55.46% to 62.24%) when imputed and true simulated
genotypes are compared in individuals typed at tag SNPs only. We,
therefore, believe that low-coverage sequencing is a practical
strategy for building imputation reference panels.
Discussion
We have proposed and implemented an LD-based method for SNP
discovery and genotype calling that combines sequence data
across many individuals. Our method, by jointly analyzing all se-
quenced individuals and borrowing information from individuals
carrying similar haplotypes, enables accurate genotype inference
from low-coverage sequencing data. We have shown through
simulation studies and analyses of data generated by the 1000
Genomes Pilot Project (The 1000 Genomes Project Consortium
2010) that when >50 individuals are sequenced, >98% genotypic
concordance rate can be achieved for SNPs with >10 copies of the
minor allele among individuals sequenced at depth $ 43. Our
simulations predict that, for a fixed sequencing depth, accuracy
will improve further as additional individuals are sequenced,
a prediction that early analyses of expanded 1000 Genomes Project
data sets confirm. For example, when the number of individuals of
European ancestry analyzed increased from 60 to 563, we were able
to detect 105% more SNPs, and the overall genotype mismatch rate
dropped from 1.61% to 0.59%.
One practical issue that we have not discussed concerns the
rapid improvement of sequencing technologies, in terms of both
increased read length and decreased sequencing error rates. Drops
in sequencing error make both SNP detection and genotype call-
ing more accurate. Similarly, longer read lengths, which reduce
the proportion of mismapped reads, should also improve overall
genotype accuracy. For example, simulations suggested that, as
sequencing error rates drop from 1.0% to 0.5% to 0.1% and ulti-
mately to 0%, the proportion of population SNPs with MAF
1%–2% that can be discovered through low-coverage sequencing
of 100 individuals at depth 23 increases from 6.7% to12.4% to
23.1% and ultimately to 60.2%.
In the 1000 Genomes Project, genotypes were called using
three independently developed methods for the analysis of low-
coverage sequence data. In addition to the methodology described
here, genotypes were initially called at the Sanger Center with
QCALL (Le and Durbin 2010) and at the Broad with GATK
(McKenna et al. 2010) and BEAGLE (Browning and Yu 2009). The
methods differ from ours in several ways. For example, QCALL uses
pre-existing genotype data to group individuals into ‘‘clades,’’ us-
ing an approximation to the local ancestral recombination graph
of each region and then uses these groupings when making each
genotype call. GATK and BEAGLE use variable length Markov
chains to describe the LD structure in each region, a method that
might be more robust to false SNPs than the approach used here.
Interestingly, evaluation of the three methods in the 1000 Ge-
nomes Project data showed that, while they each have similar ac-
curacy (Supplemental Table 3), combining results of the three
methods into an integrated call set (using a majority vote rule)
greatly improves genotype calling accuracy. For example, consensus
Figure 7. Power of association mapping by sequencing depth and number of individuals sequenced. We simulated 1500 cases and 1500 controls,
assuming a single causal variant with causal allele frequency 0.5%, 1%, or 3%. We sequenced all 3000 individuals or a random subset of 400, 1000, or
2000 individuals (equal number of cases and controls) at depths ranging from 23–303. Power was estimated using an empirical threshold determined
from 500 null sets to ensure familywise type-I error of 5%.













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































genotypes for individuals of European ancestry (by comparing both
the sites detected as SNPs and actual genotypes called) generated by
merging calls from the three independent sets (available from the
project ftp site at ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/
release/2010_11/) have average genotypic accuracy of 98.69% (com-
pared to 97.56%–98.01% in any single call set). This observation
suggests that there is still much room for refinement of individual
genotype callers for low-coverage sequence data.
The possibility of deploying low-coverage sequencing to large
sets of phenotyped samples has important implications for genetic
association studies. While more research is needed to identify
optimal designs, taking into account fixed per sample preparation
costs, sequencing costs, and genotyping costs, the results pre-
sented here already offer two lessons. First, we have demonstrated
that low-coverage designs are more powerful than deep sequenc-
ing of fewer individuals for medical sequencing studies when
a large sample size is required for the detection of modest effect
sizes or low-frequency causal variants, particularly by comparing
the overall information content and statistical power of sequenc-
ing designs with the same total sequencing effort. Specifically, we
find that it is generally preferable to sequence more individuals at
low coverage than to sequence a smaller subset of individuals at
deeper coverage. As the most recent wave of GWAS has collected
more samples than can be practically sequenced (for now), low-
coverage sequencing should provide an attractive means of using
these large existing sample sets for the next round of complex trait
studies. Second, imputation of variants detected through se-
quencing into the remainder of the sample further increases power
for association mapping.
For sequencing-based association studies of complex traits,
the trade-off between number of individuals sequenced and se-
quencing depth has important implications. For example, the only
way to comprehensively detect singletons and other very rare
variants remains to use deep sequencing and, if the focus is on such
variants, there is no current practical alternative to deep se-
quencing of samples at depth 203–303. However, for common
and low-frequency SNPs with MAF > 0.2%, we have demonstrated
that the proposed LD-based hidden Markov model can make rea-
sonably accurate inference when a large number of individuals is
sequenced. Since the relative contributions of common, low-fre-
quency, and very rare variants to complex trait variation remain
unknown, the optimal design has not yet been identified.
Recent complex trait GWAS have presented the sobering fact
that large sample sizes are key for studies of the genetic architecture
of complex traits. We anticipate the proposed methods for analysis
of low-coverage sequencing data will facilitate applications of the
emerging sequencing technologies to the study of complex traits
in very large numbers of individuals. While we have assessed the
impact of the proposed methods using single variant tests, impu-
tation-based analysis can be combined with aggregate tests for rare
variants (Li et al. 2010a; Zawistowski et al. 2010).
Methods
We have developed LD-based methods for SNP detection and
genotyping from massively parallel sequencing data, as an exten-
sion of our genotype-based imputation methods (Li et al. 2009c).
Methods used for simulated data were previously outlined in Li
et al. (2010b), based on a simple model that focused on the number
of reads containing one of two alternate alleles at each position and
in each individual. More generally, our method uses a series of
likelihoods lk(reads|G) as input. Each of these gives the likelihood
of observed read data when genotype G is assumed at location m.
For each location, 10 possible genotypes (A/A, A/C, A/T, A/G, C/C,
C/G, C/T, G/G, G/T, T/T) must be considered—allowing for single
base deletions would result in an additional set of possible geno-
types. These likelihoods can be calculated using a variety of models
for short read sequence data. Here, we use the maq error model (Li
et al. 2008), as implemented in SAMtools (Li et al. 2009a). The
model considers the base calls and associated quality scores in each
read, together with mapping quality and a simple model for arti-
facts due to small insertion and deletion polymorphisms. SAM-
tools can use short read alignments stored in SAM/BAM files to
generate this information and store the results in Genotype Like-
lihood Format (GLF) files [see http://samtools.sourceforge.net/
SAM1.pdf].
Starting with the genotype likelihoods stored in GLF files,
we first select a set of sites that are more likely to be polymorphic
based on a simple single site analysis. We then consider these sites
jointly within a hidden Markov model where haplotypes are recon-
structed by leveraging relatively short chromosome stretches shared
across individuals. A typical workflow is depicted in Figure 4, and
further details are provided in the remainder of this section.
Identification of potential polymorphic sites
The goal of this step is to focus more time-consuming analyses on
likely polymorphic sites. Input data are likelihoods for each in-
dividual at each sequenced base pair lk(reads|G), where G takes the
ten possible values {A/A, A/C, A/G, A/T, C/C, C/G, C/T, G/G, G/T,
T/T}; subscripts indicating base pair and individual are suppressed
for simplicity.
Since we only consider bi-allelic SNPs, we want to infer the
following posterior probability for each sequenced base pair:
PðM = 1fa;bgjreadsÞ where M [
1fa;bg polymorphic for alleles a and b
0 monomorphic
:
We impose the following prior based on population genetics
principles (Hudson 1991):






Here, u is the per base pair heterozygosity, typically on the order of
103 for humans. We further break down the polymorphism prior
probabilities according to mutation type defined by the alleles in
the reference genome:




2=3 if a = ref and b is the transition mutation
1=6 if a = ref and b is a transversion mutation
1=1000 otherwise
where transitions refer to purine to purine (A4G) or primidine to
primidine (C4T) mutations, while transversions refer to purine to
primidine mutations (A or G4C or T).
To infer the desired posterior probabilities, we need the like-
lihood which is proportional to the probability of the sequence











½PðGi = g j M = 1fa;bgÞ 3 PðreadsijGi = gÞg
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Pðg j M = 1fa;bgÞ =
8><
>:
p2a if g = a=a
ð1 paÞ
2 if g = b=b
2pað1 paÞ if g = a=b
0 otherwise:
Finally, we calculate the posterior as:
PðM = 1fa;bg j readsÞ} PðM = 1fa;bgÞ 3 Pðreads j M = 1fa;bgÞ:
Sites that exceed a prespecified posterior probability cutoff are
promoted as the set of likely polymorphic sites worthy of further
analysis. For data from the 1000 Genomes Low-coverage Pilot we
used 0.9 as the posterior probability cutoff.
Hidden Markov model
Our genotype calling method uses LD information and is based on
the rationale that apparently unrelated individuals often share
short stretches of chromosome. We use a hidden Markov model
where the hidden state at each marker contains a pair of indices for
the most closely related reference haplotypes for the stretch of
chromosome being considered in each individual (Li et al. 2010b;
Li et al. 2009c ). The observed data are the genotype likelihoods
reported by SAMtools (Li et al. 2009a).
In sequencing-based studies, there is typically no external
reference panel. Instead, interim haplotypes estimated for other
sequenced individuals will be used as the reference. Given n se-
quenced diploid individuals, hidden state (x,y) can take [2(n - 1)]2
different values with x, y2 {1,2,. . ., 2(n - 1)}.
Define Pr(Sm | reads) as the posterior probability for Sm, the
hidden state at marker m with reads denoting the available se-
quencing data across all sites = (reads1, reads2, . . ., readsM), where M
is the total number of polymorphisms considered. To calculate the
posterior probabilities, we adopt Baum’s forward and backward
algorithm (Baum 1972). We calculate the forward probability:
f mðx; yÞ[ Prðreads1; reads2; . . . ; readsm; Sm = ðx; yÞÞ
= Prðreadsm j Sm = ðx; yÞÞ  +
ða;bÞ
½f ða;bÞ;m1
PrðSm = ðx; yÞ j Sm1 = ða; bÞÞ
and the backward probability:
bmðx; yÞ [ Prðreadsm + 1; . . . ; readsM j Sm = ðx; yÞÞ
= +
ða;bÞ
bm + 1ða; bÞ  Prðreadsm + 1j Sm + 1½
= ða; bÞÞ  PrðSm + 1 = ða; bÞ j Sm = ðx; yÞÞ:
To calculate the forward probabilities, we note that the emission
probability at marker m:
Prðreadsm j Sm = ðx; yÞÞ
= Prðgm j Sm = ðx; yÞÞ 3 Prðreadsm j gmÞ.
In the standard formulation, forward probabilities are joint prob-
abilities and backward are conditional such that the desired pos-
terior probability:
PrðSm = ðx; yÞ j readsÞ} Prðreads; Sm = ðx; yÞÞ
= Prðreads1; reads2; . . . ; readsm; Sm = ðx; yÞÞ
 Prðreadsm + 1; . . . ; readsM jSm = ðx; yÞÞ
[f mðx; yÞ  bmðx; yÞ for m = 1;2; . . . ;M  1:
For the rightmost marker M, Pr(SM = (x, y) | reads) } Pr(reads, SM =
(x, y)) [ fM(x, y).
With the posterior probabilities calculated, genotype calls can
be conveniently inferred. For each individual at each locus, our
method generates three measures of underlying genotype: (1) the
most likely genotype: the genotype with the largest posterior
probability; (2) genotype dosage: the estimated number of copies
of an arbitrary reference allele; and (3) the posterior probabilities of
the three possible genotypes. Each of these quantities is inferred by
integrating over all possible hidden state configurations.
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